COMMUNIQUÉS West-GlobeNewswire

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update
05/05/2026
Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers Squibb Oncology pipeline strength and combination strategy highlighted through multiple clinical data updates, [...]
Santhera Publishes Agenda for its Annual General Meeting
05/05/2026
Ad hoc announcement pursuant to Art. 53 LR. Pratteln, Switzerland, May 5, 2026 – Santhera Pharmaceuticals (SIX: SANN) today published the invitation to its Annual General Meeting (AGM), which will be held on May 26, [...]
Interim report Q1 2026
05/05/2026
Strong start to the year with 7% organic sales growth and 37.8% adjusted EBITDA margin Ester Baiget, President & CEO: ” The year started strong with 7% organic sales growth against a high comparable. We delivered [...]
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
05/05/2026
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares Cash runway remains into Q4 2027, supporting continued funding of clinical programs and pre- [...]
Transplantation d’organes : ALS obtient le marquage CE pour PERLA®, une nouvelle classe de solution - PPS - et lance une étude clinique comparative
05/05/2026
COMMUNIQUÉ DE PRESSE Transplantation d’organes : ALS obtient le marquage CE pour PERLA®, une nouvelle classe de solution - PPS - et lance une étude clinique comparative Obtention du marquage CE pour PERLA®, Solution de [...]
Organ transplantation: ALS achieved CE Certification for PERLA®, The new class of solution – PPS – and launches a randomized comparative clinical trial (RCT)
05/05/2026
Press Release Organ transplantation: ALS achieved CE Certification for PERLA®, The new class of solution – PPS – and launches a randomized comparative clinical trial (RCT) ALS has received CE marking approval for PERLA [...]
Novonesis delivered strong start to the year with 7% organic sales growth in Q1
05/05/2026
COPENHAGEN, Denmark – May 5, 2026. In the first quarter of 2026, Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.8%. Ester Baiget, President & CEO: “The year started strong [...]
neurocare group AG announces MDMA approval of TMS Devices in Saudi Arabia
05/05/2026
Munich, Germany and Riyadh, Saudi Arabia - neurocare group AG (“neurocare” or the “Company”), a best practice platform for mental health and performance, is pleased to announce the Saudi Food & Drug Authority (SFDA [...]
Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer
05/05/2026
Series A financing led by 4BIO Capital, with major new investors Servier Ventures, Sound Bioventures, British Business Bank and Criteria Bio Ventures, supported by existing investors Abingworth and LifeArc Ventures [...]
GL Control Claims Evaluated: Investigating the Ingredients Benefits for Blood Sugar Trap Support
05/05/2026
GL Control Supplement Facts Reviewed: Cinnamon, Bitter Melon, Resveratrol, Licorice Root, Turmeric, and Coriander in the Blood Sugar Trap Liquid Tincture Formula for 2026 Tallmadge, OH, May 04, 2026 (GLOBE NEWSWIRE) -- [...]
Axavive Under Investigation: Inspecting the Axon Renewal Anti-Aging Benefits of the Secret Golden Seed Astragaloside IV Skin Care Supplement
05/05/2026
Axavive Ingredients Bacopa Monnieri, Centella Asiatica, Cistanche Deserticola, and Collagen Support Pathways in the Axon Renewal Skin Support Supplement Framework Explained for 2026 Tallmadge, Ohio, May 04, 2026 (GLOBE [...]
Pennant Announces First Quarter 2026 Earnings Release and Call
05/05/2026
EAGLE, Idaho, May 04, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it [...]
Axavive Claims Evaluated: The Golden Seed Switch for Healthy Skin Support
05/05/2026
Axavive Ingredients, Axon Renewal Framework, Astragaloside IV, Centella Asiatica, and Skin Support Supplement Claims Explained for 2026 Tallmadge, OH, May 04, 2026 (GLOBE NEWSWIRE) -- These statements have not been [...]
Vital Wrist Monitor & Vital Wrist Ball Under Investigation: Evaluating the Brand Claims & Product Benefits
05/05/2026
How Vital Wrist Monitor's Blood Pressure Tracking and Vital Wrist Ball's Progressive Gyroscopic Resistance Work: At-Home Wrist Health Devices Explained for 2026 Miami, FL, May 04, 2026 (GLOBE NEWSWIRE) -- Results may [...]
Providence Saint John’s Health Center Reinforces its Commitment to Maternal and Newborn Care Through Newly Named Maria Shriver Labor, Delivery and Family Wellness Unit
04/05/2026
Newly named labor, delivery and family wellness unit reflects a holistic, family-centered approach SANTA MONICA, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Providence Saint John’s Health Center is strengthening its [...]
Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026
04/05/2026
Company to Host Conference Call and Webcast Tuesday May 5 at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will report [...]
Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
04/05/2026
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous [...]
Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
04/05/2026
CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment of [...]
Biodesix Announces First Quarter 2026 Results and Highlights
04/05/2026
Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million, mid-point reflects 25% growth; Conference Call and [...]

Pages